Imanib 400MG Capsule, containing Imatinib mesylate at a dosage of 400mg, is a targeted therapy medication primarily used in the treatment of certain types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). This medication works by inhibiting specific proteins that promote cancer cell growth, thereby slowing down or stopping the progression of the disease. Imanib is composed of Imatinib mesylate, which is a tyrosine kinase inhibitor, and is available in a convenient capsule form, typically packaged in a bottle of 30 capsules. The drug is designed to be taken orally, making it easy for patients to incorporate into their daily routines. As a vital component of cancer treatment regimens, Imanib has significantly improved outcomes for many patients, offering hope and a better quality of life.

Imanib 400MG Capsule (10’s) is a medication that contains Imatinib mesylate, a potent tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer. This drug is specifically designed to target and inhibit the activity of specific proteins that promote cancer cell growth, making it effective in managing conditions such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Each capsule contains 400 mg of Imatinib mesylate, which works by blocking the signals that lead to the proliferation of cancer cells. Imanib is typically prescribed as part of a comprehensive treatment plan and is taken orally, providing a convenient option for patients. The formulation is designed to ensure optimal absorption and efficacy, making it a critical component in the management of these serious health conditions. With its targeted action, Imanib has become a cornerstone in modern oncology, offering hope and improved outcomes for patients battling these challenging diseases.

Imanib 100MG Capsule (10’s) is a medication that contains Imatinib mesylate, a potent tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Each capsule contains 100 mg of Imatinib mesylate, which works by blocking specific signals that promote the growth and division of cancer cells. This targeted therapy is designed to inhibit the activity of abnormal proteins produced by cancer cells, thereby slowing down or stopping tumor growth. Imanib is often prescribed as part of a comprehensive treatment plan and is taken orally, making it convenient for patients. The drug is well-studied and has shown significant efficacy in improving survival rates and quality of life for individuals diagnosed with these malignancies.